Presented at #ASCO26: Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM @ASCO

What I love about this news is that this is not simply a new pancreatic cancer drug. It’s that KRAS, one of cancer biology’s most notorious undruggable targets, has finally become druggable. A powerful reminder that persistence in science can eventually unlock the impossible.

Stay at the forefront of CRC care. Our new peer-exchange series explores the rapidly evolving landscape of unresectable and metastatic colorectal cancer, from emerging biomarkers and ctDNA to the latest therapeutic strategies. Explore the program here: hubs.li/Q044gxLw0 @DrKatePedersen @MayoClinic @MPishvaian @HopkinsMedicine @GIMedOnc @aparna1024 @MassGenBrigham

In a phase 1 study of the oral p53 reactivator rezatapopt in heavily pretreated patients with TP53 Y220C–mutated solid tumors, the most common adverse events were nausea and vomiting, and the overall response was 20%. Full PYNNACLE study results: nej.md/3OIQC5P Science behind the Study: Restoring Function to a Variant of p53 in Solid Tumors nej.md/3N0pQW8

Come to the next Mayo Clinic Heme/Onc Practice Update and Board Review next year. You could see @DrKatePedersen knock it out of the park with a stellar review of localized colorectal cancer! Everything you need to know (and more) on how to manage patients. @MayoCancerCare @MayoHemeOnc

🚨 The Complete Colorectal Cancer Watchlist for #GI26 From prevention to precision medicine, colorectal cancer is entering a transition year. #GI26 is not about one blockbuster drug. It is about where the field is bending. Here is the high-yield landscape every GI oncologist should watch 👇 💊 Prevention & Metabolism Abs 18 asks a disruptive question: are GLP-1 receptor agonists competing with aspirin as the next chemoprevention strategy in CRC? Abs 83 adds real-world survival data in metastatic CRC patients exposed to GLP-1s, moving this conversation beyond hypothesis into outcomes. 🎯 Targeted Therapy in First Line Abs 13 (BREAKWATER) pushes BRAF V600E–mutant CRC into new territory. Encorafenib plus cetuximab combined with chemotherapy challenges the idea that BRAF targeting belongs only after progression. 🛡️ Immunotherapy in MSI-H Disease Abs 14 (COMMIT) directly addresses a daily clinic dilemma. Is immune checkpoint inhibition alone enough, or does adding chemotherapy and bevacizumab still matter in MSI-H metastatic CRC? 📸 Local Control & Staging Abs 15 (DISCO) explores whether high-quality MRI can replace surgical staging for peritoneal metastases, raising implications for morbidity, cost, and treatment sequencing. The signal is strong across domains. If BREAKWATER delivers clinically meaningful survival, first-line BRAF CRC may be rewritten. #CRCsm #OncTwitter #MedEd #GICancer @asco @OncoAlert @OncBrothers @Larvol

🟫1L mFOLFOXIRI-Panitumumab vs mFOLFOX-Panitumumab in mCRC 5y results of TRIPLETE @JCO_ASCO ✅mOS: 41.1 vs 33.3 mo HR: 0.79 [0.63 to 0.99]; P = .049 👉ascopubs.org/doi/10.1200/JCO… #cancer #oncology #MedX #GI26 @OncoAlert @GIMedOnc